Fundraising FoxConnecticut Innovations — 2016 Investments
6 investments dated 2016 · listed companies and verified rows first · show all
Tantalus provides grid modernization technology for electric utilities, centered on a modular platform that delivers data interoperability across metering devices, substations, distribution circuits, and distributed energy resources from multiple vendors.
CleantechEnergyIoTBurnaby, US
Dermot O'Leary(Executive Officer)inPeter Londa(Executive Officer, Director)in
BoardAllen Beasley(Director)John McEwen(Director)Francis Harvey(Director)
Co-investorsPender Growth FundRedpoint Ventures
Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenous aquaporin-4 (AQP4) inhibitor designed to prevent cerebral edema (brain swelling) following severe, acute ischemic stroke.
BiotechHealthtechNew Haven, US
Dr. Pelletier(Co-founder)Dr. Boron(Founder)Marc Pelletier(Manager, Chief Executive Officer)William Boron(Co-founder)Paul McGuirk(Executive Officer)George Farr(Executive Officer)
Co-investorsBroadview Ventures
BiologicsMD is a preclinical therapeutic company developing patent-protected recombinant fusion proteins that target the parathyroid hormone receptor for treatments in hair loss, bone disorders, and oncology.
BiotechHealthtechFayetteville, US
J. David Owens(Executive Officer, Director)Robyn Goforth(Executive Officer)Rob Gensure(Executive Officer)
BoardRamsay Ball(Director)Calvin Goforth(Director, Promoter)Lynn Kirkpatrick(Director)
Co-investorsHouston Angel NetworkRobin Hood Ventures
BioWave develops patented high-frequency neurostimulation devices that deliver therapeutic stimulation deep into the body to block pain signals at the nerve source, aimed at chronic pain patients and athletes.
HardwareHealthtechMedical DevicesNorwalk, US
Bradford Siff(CEO and Secretary)Brad Siff(Founder)inRobert Adler(President)inDavid Kratovil(Chief Operating Officer)in
BoardLance Lundberg(Director)L. Charles (Duke) Meythaler(Director)
Mitotherapeutix develops siRNA-based drugs using RNA silencing to target disease-related genes, with an initial focus on a protein that regulates mitochondrial metabolic activity.
BiotechDeep TechWoodbridge, US
Mercedes Rincon(Scientific Founder)Robert Hemley(Co-Founder & COO)Robert Hennessey(Co-Founder & Chairman of Board)Jack Talley(Interim CEO)inCynthia Arbeeny(CSO)in
BoardFenel Eloi(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ruckus Media Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.